Medical device company Coloplast A/S (CPH:COLOB), a provider of medical devices and services related to ostomy, urology, continence and wound care, announced on Tuesday the availability of the new SenSura Mio Convex Flip in the US.
The company said it has expanded its SenSura Mio ostomy range with the new, innovative, first-of-its-kind SenSura Mio Convex Flip ostomy product.
Designed specifically for the outward body shapes, and the first of its kind in the ostomy market, the SenSura Mio ostomy care portfolio is intended to meet the differing needs of ostomates through its BodyFit Technology. Flat and convex barriers are common, which the SenSura Mio offers a solution for.
According to the company, SenSura Mio Convex Flip is a new solution for people with an outward body profile and is the first ostomy appliance designed specifically for those that are overweight, obese, or have parastomal bulges or hernias.
Coloplast added that with the addition of SenSura Mio Convex Flip, it continues to build out its ostomy SenSura Mio portfolio to meet more people's needs. It is difficult to make a great fit for people with outward body profiles, but the curved, star-shaped barrier can do just that.
Airiver medical receives FDA approval for central airway stenosis trial
Talphera reaches enrollment milestone in NEPHRO CRRT pivotal trial
QT Imaging signs exclusive USD33m distribution deal with Gulf Medical in Saudi Arabia
Novocure submits FDA PMA for Tumor Treating Fields therapy in pancreatic cancer
Covalon Technologies secures DTC eligibility to expand US investor access
Navamedic ASA secures final approvals for Flexilev in OraFID across Nordic markets
Oncopeptides partners with SD Pharma to expand Pepaxti access in Spain
Aptar launches bio-based nasal spray pump with Haleon's Otrivin brand
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Predictmedix AI launches mobile diabetes screening platform in India
Navamedic's medical device OraFID approved as primary package for a pharmaceutical product
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions